The Pandemic Preparedness Diagnostics Market is projected to register a strong CAGR during the forecast period (2026-2031).
The Pandemic Preparedness Diagnostics Market is expanding as global healthcare systems prioritise early detection and outbreak response. These diagnostics enable rapid identification of emerging pathogens, supporting surveillance and containment strategies. Increasing government investments, technological advancements, and global health initiatives are driving strong demand for advanced diagnostic solutions.
Pandemic preparedness diagnostics are technologies that allow for the identification, monitoring, and effective management of infectious disease outbreaks through the use of multiple tests. Such technologies include quick assays, molecular tests, and point-of-care tools, which aid in detecting pathogens quickly. With continued global investments in health security infrastructure and preparedness being a continued trend through 2025, the pandemic preparedness diagnostic market continues experiencing rapid growth. The creation of resilient diagnostic systems that can react to quickly to emerging risks will be the increasing focus of governments, healthcare providers and private entities. This ongoing trend, along with evolution towards decentralised testing technologies, artificial intelligence integration, and multiplex assay development, will continue reshaping the pandemic preparedness diagnostic sector as diagnostics grow increasingly important in terms of real-time monitoring of pandemic response, outbreak identification and control strategies around the world.
Rising Threat of Emerging Infectious Diseases: In recent years, an increased incidence of newly identified infectious disease outbreaks has significantly increased the market for rapid and scalable diagnostic methods due to the number of recent incidents of disease outbreak (e.g., COVID-19, flu strains, and newer virus types).
Government Initiatives and Funding Programs: Many governments and global health organizations are investing heavily in diagnostic preparation through infrastructure development programs which should positively influence market development as well.
Advancements in Molecular and Rapid Diagnostics: Many current diagnostic technologies are undergoing continual advancement; molecular and rapid diagnostics such as PCR, NGS, and rapid antigen detection assays will provide significantly increased speed and precision to aid health officials in effectively controlling spread during epidemics.
Increasing Demand for Real-Time Surveillance: Healthcare systems will continue to require continuous identification and monitoring of pathogens to permit timely intervention by health officials; therefore, there will be continuing acceleration of adoption of advanced diagnostic platforms operating with integrated data and analytics technologies.
While the market has many opportunities, it is faced with challenges including but not limited to; cost restrictions of using advanced diagnostic technologies, regulations surrounding the use of diagnostics, and disparities between health infrastructures in different world regions. Data privacy concerns, supply chain disruptions, and additional barriers could also present a risk to future market expansion. Conversely, the emergence of artificial intelligence or other digital metrics-based diagnostic platforms, increasing use of home-based diagnostic testing, and the need for portable/multiplex diagnostic platforms will continue to stimulate development and investment in the diagnostic marketplace. In combination with growing global interest in the health security of countries around the world, there is likelihood of continuing increases in investment and innovation toward diagnostics, resulting in a strategic asset supporting implementation of both future epidemic and long-term outbreak response systems.
June 2025: bioMérieux strengthened its antimicrobial resistance diagnostics capabilities by acquiring assets from Day Zero Diagnostics, a company specialising in genome sequencing and machine learning-based infectious disease detection. This acquisition enables faster identification of pathogens and their antibiotic resistance profiles directly from blood samples, significantly reducing diagnostic time from days to hours.
The market is segmented by product type, technology, application and geography.
Testing Kits are considered to be the most important part of the diagnosis and rapid, scalable testing process during an outbreak. Testing kits consist of PCR assays, antigen tests, and multiplex assays designed for the rapid detection of pathogens. They can be transported easily and used easily. Testing Kits can help with mass screening or urgent emergency response situations. Because of ten years of decentralised tests with quick turnaround, the demand will grow in 2026 and into the future. Consequently, governments and health organisations are stockpiling advanced Test Kits for preparedness to deal with future pandemic outbreaks by deploying them at a rapid rate in the situation of a high-risk area or outbreak.
Polymerase Chain Reaction (PCR) technology remains the gold standard technology for pandemic diagnostics by offering the ability to detect pathogens (e.g., viruses, bacteria) at early stages of infection with a great deal of precision. Consequently, it is an important technology for controlling outbreaks. In 2025, with updates in real-time and portable PCR technology being developed, testing will continue to become more and more rapid and possible over a broader range of people. While PCR is used in many central laboratories and point-of-care locations, PCR also provides the capability of multiple pathogen/variant detection to provide important data for continued surveillance of infectious diseases and assist in the development of strategies for effective response to outbreaks. PCR is a necessity in pandemic preparedness diagnostics and supporting the diseases.
Surveillance of disease is the primary use of integrating diagnostic technologies with digital health applications and data analytics to support the continuous monitoring of infectious diseases and the earlier detection of potential outbreaks. The governments and global health organisations will utilise relationships with digital health technology and governments to enhance and integrate surveillance systems throughout the world to minimise the risk of a global outbreak occurring.
The North American market is at the forefront of pandemic preparedness diagnostic capabilities because of its superior healthcare infrastructure and the investment made by the government in funding systems for response to outbreaks. It has advanced laboratory systems and has rapidly adopted molecular and point-of-care diagnostic systems. Awareness of these technologies is high, with established and successful surveillance systems in place, as well as ongoing investments into artificial intelligence-based diagnostic technology to help with early identification and responses to outbreaks. The presence of large diagnostic companies and public health agencies has further empowered growth in the market and innovation in the development of diagnostic testing systems.
The healthcare systems in South America are improving and providing various options for pandemic preparedness; therefore, many governments will continue to invest in health care throughout the region. In Brazil and Argentina, there are efforts underway to strengthen hospital services (i.e., laboratory facilities) related to diagnostics and improve access to testing. Additionally, the increased awareness of how to effectively manage infectious diseases and the importance of early detecting have assisted with the implementation of these diagnostic measures in both countries. However, due to the limited resources available to many South American nations, there may be restrictions on the speed of growth within South America. It is anticipated that ongoing healthcare reform initiatives will lead to continued long-term growth within the region.
The European market is steadily growing in both size and scope, supported by the presence of strong governmental public health systems and cross-border disease surveillance initiatives. As seen across many parts of the world, there is an increased focus from governments on both acquiring advanced diagnostic technology and strengthening laboratory capacity to enable rapid identification of disease outbreaks. A further contributing factor to the growth of the diagnostics industry in Europe is the increased interest in the development of new antimicrobial agents as well as the ongoing development of pandemic preparedness programs which will lead to greater demand for all forms of testing. The collaboration between research organisations and health providers across Europe is producing many innovations in the field of diagnostics. Both regulatory support as well as a focus on rapid identification of diseases are providing further opportunities for consistent growth in the European diagnostics industry.
Middle Eastern & African regions are beginning to see the benefits of investing in improving the infrastructure and developing surveillance systems for healthcare. Many countries in the Middle East have initiated the use of advanced diagnostics to help improve the response to infectious disease outbreaks. Similarly, through international aid and support from public health agencies, many African countries now have improved access to diagnostic services. Both regions will continue to see increased growth of demand for diagnostics due to the rising burden associated with infectious disease and the priority placed on early detection. As healthcare infrastructure improves over time, the demand for diagnostic services will continue to grow steadily within both regions of the world.
The Asia Pacific diagnostics market is one of the fastest growing due to high levels of population density, higher levels of infectious disease outbreak risk, and/ or expanding healthcare infrastructures. Governments across Asia Pacific, including countries such as China, India, and Japan, are investing in upgrading their diagnostic infrastructures as well as implementing new disease surveillance systems. The increased consumer demand for early identification of infectious diseases and lower-cost diagnostic solutions has led to the rapid acceptance of diagnostic technologies in this region. The continuing growth of digital health solutions as well as mobile point of care diagnostics, will further drive market growth in this region, both in urban and rural areas.
· Thermo Fisher Scientific
· Roche Diagnostics
· Abbott Laboratories
· Danaher Corporation
· bioMérieux
· QIAGEN
· Hologic
· BD (Becton, Dickinson and Company)
· Cepheid
· Seegene
The industry is in the process of consolidation as players target the provision of “Pandemic Preparedness Diagnostics Market” toolchains.
Abbott leads the market for wearable biosensors, particularly in the area of continuous glucose monitoring (CGM). Their FreeStyle Libre system has become the standard against which all others are compared, allowing patients with diabetes to monitor their blood sugar levels in real time without the hassle of repeatedly pricking their fingers. Abbott is working to combine biosensors with mobile platforms, so patients have an ongoing picture of their health status based on this continuous data. Abbott's highly developed global footprint, commitment to innovation and development of digital health ecosystems through partnerships have helped them cement their position as the leader in wearable diagnostics.
BioMérieux is a top provider of diagnostic services for both infectious diseases and testing for resistance against antibiotics. Through its combined offerings of automated systems, test reagents and software, bioMérieux's products allow hospitals and/or laboratories to perform rapid identification of microorganisms as well as provide the test results necessary for initiating the most appropriate and effective treatment options for patients with an infectious disease. In addition, bioMérieux places a strong emphasis on developing innovative technologies and techniques to enhance the ability to accurately and quickly detect infections via microbiological as well as molecular diagnostic methods. bioMerieux's extensive global reach, coupled with its expertise in the discipline of infectious disease, uniquely position bioMérieux to assist in the drive to advance AMR diagnostic products and services and, subsequently, improve global healthcare delivery.
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Growth Rate | Ask for a sample |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product Type, Technology, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |